Intuitive Surgical, Inc.

- The discussion around capital placements and system trade-ins suggests a progressive trading cycle for da Vinci systems over multiple years. - There is an ongoing build-up of demand, with 110 da Vinci 5 systems placed in Q3 2024. - The company expects placements in the U.S. to progressively shift toward trade-ins as the broad launch of da Vinci 5 moves forward. - Outside the U.S., system placements remain solid with 160 systems placed in Q3 2024, including early placements of Ion systems in Europe and China. - Leasing arrangements are increasing, representing 58% of Q3 system placements, which helps customers access capacity without large capital expenditures. - Government budget pressures in Europe and broad stress in China imply some constraints in those markets. - Overall, the orderbook appears stable with progressive growth in trade-ins and placements aligned with expected launches and market conditions, though specific orderbook numbers or pending orders were not explicitly disclosed.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company ended Q3 with cash and investments of $8.3 billion, higher than $7.7 billion in the prior quarter, indicating strong liquidity. - There is no indication of an immediate need for capital raising. - Capital expenditures are expected between $1 billion and $1.2 billion primarily for facility construction, funded by existing cash. - Operating leases with usage-based agreements are growing but are a part of normal business operations, not new fundraising. - Management emphasizes a stable capital environment and does not discuss new debt or equity issuance plans through 2025.

- Capital expenditures for 2024 are estimated in the range of $1 billion to $1.2 billion, primarily for planned facility construction activities (Page 3). - Expect capital investments to support ramp-up of da Vinci 5 system supply capabilities through mid-2025 (Page 5). - Progressive trade-in cycles over multiple years with refurbishment of da Vinci systems for site of care segmentation internationally and in the U.S. (Page 4). - Investment in innovation continues both in hardware development and software upgrades, with semi-routine software updates planned to enhance system features ahead of broad da Vinci 5 launch (Page 5). - Broader focus includes investments supporting scaling of manufacturing facilities, notably INA manufacturing in Mexicali (Page 3). - No explicit changes to capital allocation strategy communicated; management balances profitability targets with investment in growth opportunities (Page 4).

- U.S. procedure growth is stable with strong interest in da Vinci 5, supporting ongoing revenue growth. - Europe faces pressure due to government budget constraints, with uncertain impact on near-term capital placements. - China experiences broad healthcare market stress and competitive pressure from domestic entrants; expected to persist for several quarters. - Procedure growth remains balanced between deepening penetration in existing procedures and exploring new, niche markets (e.g., new indications for Ion and SP systems). - Da Vinci 5 is gaining traction with over 12,000 procedures in six months, indicating strong adoption and potential for expanded sales. - International markets (like Japan, Korea, Europe) show mixed conditions but are part of ongoing commercial efforts. - Usage-based agreements are increasing, aiding placements and procedure growth, especially in the U.S. - Overall, growth driven by product innovation, expanding procedure categories, and digital ecosystem enhancements.

- Procedure growth outlook for 2024 raised to 16-17%, with international headwinds in Asia noted. - Pro forma gross profit margin expected at 68.5%-69% for 2024; gross margins may be slightly lower in 2025 due to increased depreciation from new product ramp-up. - Pro forma operating expense growth for 2024 now forecasted at 10-12%, slightly reduced from prior 10-13%. - No management objective to exceed 40% operating margins; recent operating margin was 37%. - Pro forma EPS increased 25% year-to-date compared to prior year, with Q3 2024 pro forma EPS at $1.84 vs. $1.46 in prior year. - Depreciation from da Vinci 5 production ramp expected to weigh on margins temporarily but improvements in efficiency anticipated. - Usage-based arrangements and trade-in refurbishments may affect capital placements and P&L but aimed at stable, accretive impact. - In sum, company projects stable to moderate growth in earnings with balanced investment and margin objectives over the midterm.